Vitreomacular Traction Syndrome

Vitreomacular Traction Syndrome means the clear gel that fills the eye—the vitreous—is pulling on the macula, which is the sharp-seeing center of the retina. The macula helps you read, recognize faces, and see fine details. As we age, the vitreous usually shrinks and peels away from the retina in a process called posterior vitreous detachment (PVD). In VMT, this separation is incomplete: a piece of vitreous stays stuck to the macula and tugs on it. That tug changes the normal shape of the macula and can blur or distort central vision. Doctors see and measure this with optical coherence tomography (OCT), a scan that shows cross-sections of the retina. The International Vitreomacular Traction Study (IVTS) Group formalized how VMT is defined and classified on OCT: vitreomacular adhesion (VMA) is attachment without distortion, while VMT is attachment with visible distortion (such as small cysts, schisis splits, edema, or even a small detachment under the center). PubMedPortale OCulistica Amedeo Lucente

Vitreomacular traction (VMT) syndrome happens when the eye’s gel (the vitreous) stays stuck to the center of the retina (the macula) and pulls on it. Normally, as we age, the vitreous liquefies and lets go of the macula (a clean “posterior vitreous detachment”). In VMT, the vitreous only partly lets go. A small, firm attachment remains and tugs on the macula. That pulling distorts the macula’s delicate layers, so straight lines look wavy (metamorphopsia), fine print blurs, and central vision can drop. Some eyes release on their own; others stay stuck and may form complications such as macular edema, an epiretinal membrane (a thin scar on the macula), or even a full-thickness macular hole that threatens central vision.

In short:

• VMA = vitreous still attached at the macula, no macular shape change, often no symptoms.

• VMT = vitreous attached and pulling, causing shape change and symptoms such as blur and distortion. This spectrum can, in some patients, lead to more serious issues like a full-thickness macular hole if traction persists or worsens. PubMedEyeWikiAmerican Academy of Ophthalmology

Vitreomacular Traction (VMT) Syndrome is a condition where the vitreous gel partially separates from the back of the eye but remains abnormally attached at the macula—the tiny central area responsible for sharp, detailed vision. This partial attachment pulls the macula forward, like a small piece of tape tugging on a thin sheet. The pulling can distort vision, cause wavy lines, blurry central vision, and sometimes central blind spots. VMT can stay stable, spontaneously release, or progress to complications such as macular edema, epiretinal membrane (ERM), or a macular hole. Diagnosis relies on OCT, which shows the exact point and pattern of traction.

Types

1. By width of the traction (how wide the stuck area is on OCT):

• Focal VMT: the stuck area is small (IVTS uses ≤1,500 micrometers). Think “pinpoint pulling.” Focal traction tends to concentrate force at the center and can cause focal cysts or a small lift of the fovea (the very center of the macula). Some studies and clinics further sub-stratify focal vs broad using slightly different cutoffs (like 400 µm), but the IVTS standard uses 1,500 µm. PubMedPMCRetina Today

• Broad VMT: the stuck area is wider (≥1,500 micrometers). Think “sheet-like pulling.” Broad traction spreads force across a larger area of the macula and is more likely to cause diffuse thickening, vascular leakage, or cystoid macular edema. PubMedPMCen.octclub.org

2. By traction shape (the profile of the pull seen on OCT):

• V-shaped traction: the vitreous lifts up like a tent over the macula with two points of attachment forming a “V.” This can focus traction at the foveal center.

• J-shaped traction: the vitreous peels more on one side, creating a curved “J-like” adhesion on the other side that continues to tug on the macula. Both patterns are ways doctors describe how the gel is pulling and where the stress falls on the macula. PMC

3. By association with other macular interface problems:

• Isolated VMT: traction without other obvious surface problems.

• VMT with Epiretinal Membrane (ERM): traction plus a thin, cellophane-like film on the macula’s surface that adds tangential (sideways) pull. ERM can worsen distortion and blur. Risk factors for ERM include age, diabetes, and cholesterol disorders. AAO JournalNCBI

4. By outcome risk (clinical behavior):

• Stable/observational VMT: traction that may be watched because symptoms are mild and vision is relatively good; some cases release on their own.

• Progressive/complicated VMT: traction associated with worsening vision, worsening edema, or progression to conditions like macular hole, schisis (splitting of layers), or tractional macular detachment—these may need treatment. Review of Ophthalmology

Causes

Below are 20 plain-language causes and associations. In many people, more than one factor can apply.

1. Normal aging with incomplete PVD: As the vitreous gel shrinks, it sometimes does not peel off cleanly and stays stuck to the macula, creating traction. This is the most common pathway to VMT. PubMed

2. Anomalous posterior vitreous detachment: The vitreous separates in an irregular pattern, leaving strong focal adhesions that keep pulling on the macula. PubMed

3. Epiretinal membrane (ERM): A thin scar-like film can form over the macula and add sideways pulling forces that exacerbate VMT. AAO Journal

4. Diabetic retinopathy: Long-standing diabetes can lead to new vessels and fibrous tissue that increase vitreoretinal adhesions and traction around the macula. PubMed

5. Retinal vein occlusion: Blocked veins can cause swelling and tissue changes that strengthen vitreous attachments and encourage traction.

6. Uveitis (intra-ocular inflammation): Inflammation can cause membranes to form on the retinal surface, increasing stickiness and pull.

7. High myopia (very nearsighted eyes): Elongated eyes have altered vitreous and macular architecture, which can predispose to abnormal adhesion and traction.

8. Ocular trauma: A strong jolt can change vitreous consistency or cause focal adhesions that later pull on the macula.

9. Recent cataract surgery: After surgery, the vitreous can shift, and in some eyes this coincides with progression of PVD and abnormal adhesions that create traction.

10. Prior retinal detachment or repair: Scarring and changes after detachment or surgery can strengthen macular adhesions.

11. Vitreous hemorrhage: Blood in the vitreous can organize into fibrous strands that catch and pull on the retina as they contract.

12. Radiation retinopathy: Radiation-related vessel and tissue changes can alter the vitreoretinal interface and promote traction.

13. Sickle cell or ischemic retinopathies: Ischemia and neovascular tissue can create stronger tractional elements near the macula.

14. Post-laser photocoagulation: In some scenarios, scarring near the macula may alter local traction dynamics.

15. Macular edema from other causes: Chronic swelling can reorganize macular tissues and glue the gel to the surface.

16. Inherited vitreoretinal disorders (e.g., Stickler/Wagner spectrum): Congenital variations in collagen and vitreous structure can predispose to abnormal adhesion and traction.

17. After intravitreal injections or procedures: Very rarely, interface changes following procedures may contribute to adhesion behavior.

18. Retinal vascular diseases (e.g., Eales disease, inflammatory vasculitis): Fibrovascular changes can strengthen vitreoretinal attachments.

19. Age-related macular degeneration with VMA: Some eyes with AMD also show persistent adhesion that can alter macular mechanics; traction can be part of that interface picture even if AMD is the primary disease.

20. Idiopathic (no clear cause): Sometimes VMT occurs without any identifiable trigger apart from normal aging.

(Notes: The IVTS emphasizes that VMA/VMT are commonly the result of normal vitreous aging; several of the associated diseases above—like diabetes or ERM—change the vitreoretinal interface and increase the chance of symptomatic traction.) PubMedEyeWiki

Symptoms

1. Blurred central vision: Fine detail looks fuzzy, especially when reading or recognizing faces. EyeWikiAmerican Society of Retina Specialists

2. Metamorphopsia (distortion): Straight lines look wavy or bent, and squares look warped. This happens when traction wrinkles the macula. American Society of Retina SpecialistsAll About Vision

3. Micropsia: Things look smaller than they really are; the macula’s image-mapping is stretched by traction. American Society of Retina Specialists

4. Reduced sharpness (decreased acuity): The smallest letters on the eye chart become harder to read. American Society of Retina Specialists

5. Central scotoma (blank spot): A small gray or empty patch can appear in the center if traction lifts or damages the fovea. EyeWiki

6. Photopsia (flashes of light): Quick flashes can occur with vitreous movement tugging on the retina. American Society of Retina Specialists

7. Difficulty reading: Letters swim, lines curve, and reading speed drops because central vision is unstable. EyeWiki

8. Trouble with faces: Distortion makes facial features look off, which is frustrating in daily life.

9. Eyestrain and headaches while focusing: The brain fights the distorted input and tires easily.

10. Poor contrast: Subtle shades and low-contrast print are harder to see when the macula is swollen or wrinkled.

11. Color dulling: Colors may seem less vivid if the fovea is affected.

12. Worse vision in dim light: Central distortion is more noticeable when lighting is not ideal.

13. Depth misjudgment: When one eye is more affected, judging distances becomes tricky.

14. Aniseikonia (image size mismatch between eyes): If one macula is distorted, images look different sizes between the two eyes, making binocular vision uncomfortable.

15. Sudden drop in central vision (uncommon): Rarely, traction abruptly detaches the fovea, causing sudden central vision loss; this is urgent. EyeWikiReview of Ophthalmology

Diagnostic tests

Below are 20 tests grouped into Physical Exam (5), Manual Tests (3), Lab & Pathological Tests (5), Electrodiagnostic Tests (3), and Imaging Tests (4). Each name is followed by a plain explanation of what it is, why it’s done, and what it can show in VMT.

A) Physical Exam

1. History-taking (symptom interview)
   Your eye-care professional asks about blur, distortion, micropsia, flashes, and how long they’ve been present. They ask about diabetes, eye surgery, trauma, or inflammation. This guides the rest of the workup and helps link traction to underlying causes like ERM or diabetic eye disease. EyeWiki

2. Best-Corrected Visual Acuity (BCVA)
   This is the standard eye-chart test with optimal lenses. It quantifies how much central sharpness is reduced and acts as a baseline to track changes if the traction improves (spontaneously or after treatment) or worsens over time.

3. Pupil exam (including RAPD check)
   The doctor shines a light to assess pupil reaction and looks for a relative afferent pupillary defect (RAPD) that might hint at more widespread retinal or optic nerve issues. Although VMT mainly affects the macula, a normal pupil test supports a localized macular problem.

4. Color vision and contrast sensitivity
   Simple plates or contrast charts check whether color discrimination and contrast are reduced—common when the fovea is swollen or distorted by traction.

5. Dilated slit-lamp biomicroscopy of the macula
   After dilating the pupil, the clinician uses a slit lamp with special lenses to examine the macula. They may see subtle surface wrinkling, a hint of epiretinal membrane, or loss of the normal foveal reflex. This bedside view complements imaging, especially when arranging OCT.

B) Manual Tests

6. Amsler Grid
   You look at a small grid of straight lines with one eye at a time. Wavy lines, missing boxes, or central blur indicate metamorphopsia or a scotoma caused by a distorted macula. This is a simple, at-home-friendly way to monitor symptoms over time. All About Vision

7. M-CHARTS (metamorphopsia quantification)
   This is a set of dotted lines with varying spacing to measure how severe the warping is. It turns a subjective complaint (“lines look wavy”) into a number that can be tracked.

8. Preferential Hyperacuity Perimetry (PHP)
   This handheld test detects small distortions by showing targets that exploit the eye’s fine positional sense (hyperacuity). It maps where distortion is worst and can be used serially to monitor change.

C) Lab & Pathological Tests

These are not required for every patient with VMT. They are used selectively when the history or exam suggests a systemic driver like diabetes or inflammation.

9. Fasting glucose and HbA1c
   Checks for diabetes and overall blood-sugar control. Poor control is linked to retinal changes that can strengthen vitreoretinal adhesions and worsen traction behavior. PubMed

10. Lipid profile
    High cholesterol and lipid disorders associate with ERM and other macular conditions; optimizing lipids supports retinal health and may impact recurrence risks. NCBI

11. ESR and CRP (inflammatory markers)
    Elevated markers suggest inflammation (e.g., uveitis), which can cause membranes and stickiness at the vitreoretinal interface that potentiate traction.

12. Autoimmune/uveitis panel (e.g., ANA, RF, HLA-B27 as indicated)
    Chosen case-by-case when history points to autoimmune disease. Positive results support a role for ocular inflammation in the traction picture.

13. Infectious serology (as indicated)
    Targeted tests (e.g., syphilis, TB interferon-gamma release assay, toxoplasma) are ordered if the clinical story suggests an infectious uveitis that could contribute to epiretinal membranes or traction.

D) Electrodiagnostic Tests

14. Full-Field Electroretinography (ffERG)
    Electrodes record the retina’s overall electrical response to flashes. In isolated VMT, global function is often near normal; ffERG is helpful when doctors suspect a wider retinal problem beyond the macula.

15. Multifocal Electroretinography (mfERG)
    Measures local retinal function across the macula. In VMT, mfERG can show reduced central responses that match the area under traction and can improve if traction releases.

16. Visual Evoked Potentials (VEP)
    Electrodes on the scalp measure the brain’s response to visual signals. VEP is useful when the team wants to confirm that the visual pathway beyond the eye is working properly, supporting that vision loss is macular (traction-related) rather than optic-nerve-related.

E) Imaging Tests

17. Optical Coherence Tomography (OCT)
    This is the key test. OCT shows a high-resolution cross-section of the macula and the vitreous face. In VMT, OCT reveals persistent attachment with macular distortion—such as cysts, schisis (layer splitting), or a small detachment. OCT also classifies traction as focal or broad (≤ or ≥ 1,500 µm in IVTS). It is essential for diagnosis, classification, and monitoring over time. PubMedPortale OCulistica Amedeo LucentePMC

18. OCT-Angiography (OCT-A)
    OCT-A maps capillary flow without dye. In VMT, it helps assess whether traction-related edema or structural changes are disrupting the foveal avascular zone or macular perfusion, and it can rule out coexisting macular diseases.

19. B-scan ocular ultrasonography
    Ultrasound is useful when media are cloudy (e.g., cataract or vitreous hemorrhage) and OCT is hard to obtain. It can show whether the vitreous is still attached at the macula and can detect broader tractional problems.

20. Fluorescein angiography (FA)
    A dye-based test that shows leakage from retinal vessels. In VMT, FA can reveal macular edema patterns or associated vascular disease (e.g., diabetes or vein occlusion) that influence traction severity and management. FA complements OCT when swelling patterns are unclear. en.octclub.org

Non-pharmacological treatments (therapies and other measures)

Note: These measures support comfort, safety, and monitoring. They do not dissolve the vitreous. Some eyes will release traction naturally; others will need a procedure or surgery.

1. Education and shared decision-making
   Purpose: Help you understand VMT, options, and realistic outcomes.
   Mechanism: Reduces anxiety, supports adherence and timely care (e.g., reporting new symptoms fast).

2. Observation with scheduled OCT monitoring
   Purpose: Watch for spontaneous release or early complications.
   Mechanism: Regular OCT detects change in traction strength, edema, or hole formation so treatment isn’t delayed.

3. Home Amsler grid checks
   Purpose: Simple daily/weekly self-test for new waviness or scotomas.
   Mechanism: You stare at a grid; new distortions often mean traction or edema is changing.

4. Optimize systemic health (diabetes, blood pressure, lipids)
   Purpose: Reduce retinal stress and swelling risk.
   Mechanism: Better microvascular control improves macular fluid balance and healing capacity.

5. Treat ocular surface dryness
   Purpose: Improve overall visual comfort while you monitor vision.
   Mechanism: Lubrication enhances image quality and reduces fluctuating blur unrelated to the macula.

6. Avoid eye rubbing and heavy Valsalva strain
   Purpose: Minimize sudden tractional spikes.
   Mechanism: Rubbing/straining can transiently raise eye pressure and tug the vitreoretinal interface.

7. Safe lighting and high-contrast reading tools
   Purpose: Reduce visual strain from distortion.
   Mechanism: Bright, even light and contrast-boosting lamps/magnifiers improve legibility.

8. Low-vision aids when needed
   Purpose: Maintain independence if central vision is reduced.
   Mechanism: Magnifiers, electronic readers, and large-print tools enlarge or enhance text.

9. Task modification and visual ergonomics
   Purpose: Keep working/reading comfortably.
   Mechanism: Larger fonts, increased spacing, and frequent breaks ease the burden of metamorphopsia.

10. Smoking cessation
    Purpose: Protect retinal microcirculation.
    Mechanism: Quitting smoking improves oxygen delivery and reduces oxidative stress to retinal cells.

11. Nutrition pattern for retinal health
    Purpose: Support the retina’s antioxidant defenses (see food section).
    Mechanism: Leafy greens, fish omega-3s, and colorful fruits provide carotenoids and anti-oxidants.

12. Weight, fitness, and glycemic control
    Purpose: Strengthen small vessel health and reduce edema tendency.
    Mechanism: Exercise and smart diet stabilize glucose and reduce inflammation.

13. Blue-light hygiene and glare control
    Purpose: Increase comfort if the macula is sensitive.
    Mechanism: Anti-glare coatings, appropriate device settings, and matte screens reduce scatter.

14. Safe driving strategies
    Purpose: Prevent accidents during periods of wavy or blurred central vision.
    Mechanism: Limit night driving, increase following distance, and seek prompt eye care if changes arise.

15. Fall-prevention at home
    Purpose: Safety if vision fluctuates.
    Mechanism: Eliminate tripping hazards, add night lights, and use handrails.

16. Treat ocular inflammation if present (non-drug measures)
    Purpose: Lower the inflammatory contribution to edema.
    Mechanism: Cool compresses/artificial tears can support comfort; true inflammation needs medical therapy (see drugs).

17. Post-cataract surgery vigilance
    Purpose: Detect traction changes after surgery when vitreous shifts are common.
    Mechanism: Early OCT and symptom checks catch edema or macular hole early.

18. Prompt care after eye trauma
    Purpose: Prevent traction worsening or retinal tears.
    Mechanism: An exam after blunt injury is essential; trauma can destabilize the vitreoretinal interface.

19. Medication review
    Purpose: Identify drugs that can worsen macular edema (e.g., certain systemic meds).
    Mechanism: Your doctor coordinates with your other clinicians to adjust if needed.

20. Mental health support
    Purpose: Ease anxiety/depression linked to visual changes.
    Mechanism: Counseling and peer support improve coping and adherence.

---

Drug treatments

Important: Your retina specialist individualizes dosing. Any injection in the eye carries risks (infection, bleeding, pressure rise, retinal tears). The medicines below target traction, edema, or co-existing retinal disease.

1. Ocriplasmin (intravitreal proteolytic enzyme)
   Class: Pharmacologic vitreolysis agent.
   Typical dose/time: 0.125 mg in 0.1 mL, single intravitreal injection in a controlled setting.
   Purpose: Try to chemically release vitreous adhesion at the macula.
   Mechanism: Cleaves protein links (laminin/fibronectin) at the vitreoretinal interface to promote detachment.
   Key side effects: Temporary vision change, photopsia, dyschromatopsia (color shift), floaters, rare retinal tears/detachment, lens subluxation, or inflammation.

2. Ranibizumab (anti-VEGF intravitreal)
   Class: VEGF inhibitor.
   Typical dose/time: 0.5 mg monthly loading; interval may extend per disease.
   Purpose: Treat macular edema when VMT coexists with conditions like diabetic macular edema or neovascular AMD; may lessen edema related to traction but does not reliably release traction.
   Mechanism: Blocks VEGF to reduce vascular leakage and swelling.
   Key side effects: Endophthalmitis risk, transient IOP rise, rare inflammation; systemic vascular events are rare but discussed.

3. Aflibercept (anti-VEGF intravitreal)
   Class: VEGF-A/VEGF-B/PlGF trap.
   Typical dose/time: 2 mg every 4 weeks initially, then often every 8 weeks (condition-dependent).
   Purpose/Mechanism/Side effects: As above; broader ligand binding may reduce edema in some contexts.

4. Bevacizumab (anti-VEGF, off-label intravitreal)
   Class: VEGF inhibitor.
   Typical dose/time: 1.25 mg every ~4 weeks as needed.
   Purpose: Cost-effective option for edema due to coexistent disease; not a traction releaser.
   Side effects: As with anti-VEGF agents.

5. Dexamethasone intravitreal implant (0.7 mg)
   Class: Corticosteroid implant.
   Typical dose/time: One implant lasting ~3–6 months; repeat PRN.
   Purpose: Reduce inflammatory macular edema (e.g., uveitis, post-op).
   Mechanism: Potent anti-inflammatory action stabilizes blood-retinal barrier, reducing fluid.
   Key side effects: Cataract progression, steroid-induced glaucoma, IOP spikes, infection risk.

6. Triamcinolone acetonide (intravitreal or sub-Tenon’s)
   Class: Corticosteroid.
   Typical dose/time: Intravitreal 2–4 mg (0.05–0.1 mL of 40 mg/mL), single dose; repeat PRN.
   Purpose: Short-term edema control when inflammation contributes.
   Mechanism: Anti-inflammatory; reduces vascular permeability.
   Key side effects: IOP rise, cataract, floaters, rare infection.

7. Acetazolamide (oral carbonic anhydrase inhibitor)
   Class: Systemic CAI.
   Typical dose/time: 250 mg orally BID (or 500 mg SR BID) short courses as directed.
   Purpose: Sometimes helps cystoid macular edema in select cases; adjunctive only.
   Mechanism: Enhances fluid transport across retinal pigment epithelium, promoting macular dehydration.
   Key side effects: Tingling, altered taste, fatigue, kidney stones, sulfa allergy caution; avoid in certain kidney issues or pregnancy unless specialist approves.

8. Topical dorzolamide 2% or brinzolamide 1% (carbonic anhydrase inhibitors)
   Class: Topical CAI drops.
   Typical dose/time: TID (dorzolamide) or BID–TID (brinzolamide).
   Purpose: May help mild cystoid edema in some scenarios; modest effect.
   Mechanism: Similar epithelial pump support, but topical delivery is weaker than systemic.
   Key side effects: Ocular irritation, bitter taste, rare allergy.

9. Topical NSAIDs (e.g., bromfenac 0.09%, nepafenac 0.1–0.3%)
   Class: Non-steroidal anti-inflammatory drops.
   Typical dose/time: QD–BID, weeks to months if indicated.
   Purpose: Supportive therapy for post-operative or inflammatory macular edema; not a traction reliever.
   Mechanism: COX inhibition lowers prostaglandins that drive edema.
   Key side effects: Stinging, rare corneal issues with prolonged use; use under supervision.

10. Peri-ocular steroid injections (e.g., sub-Tenon’s triamcinolone 40 mg)
    Class: Regional corticosteroid.
    Typical dose/time: Single injection; repeat PRN per specialist.
    Purpose: Edema control when intravitreal is not preferred.
    Mechanism/Side effects: As with steroids; IOP monitoring is essential.

Reality check: Among drugs, only ocriplasmin directly targets the traction itself. The others primarily treat edema or coexisting retinal disease. If traction persists and vision suffers, a procedure (gas) or surgery (vitrectomy) is often needed.

---

Dietary molecular supplements

Always discuss supplements with your clinician, especially if pregnant, on blood thinners, or with chronic disease. Typical doses are general; your doctor may advise differently.

1. Omega-3 fatty acids (EPA/DHA)
   Dose: ~1,000 mg/day combined EPA+DHA (food + supplement).
   Function/Mechanism: Anti-inflammatory lipid mediators support retinal cell membranes and microcirculation.

2. Lutein + Zeaxanthin
   Dose: 10 mg lutein + 2 mg zeaxanthin/day (typical).
   Function/Mechanism: Macular carotenoids concentrate in the fovea, filtering blue light and quenching free radicals.

3. Vitamin C
   Dose: 500 mg/day (diet preferred; supplement if diet is poor).
   Function/Mechanism: Antioxidant recycling partner for vitamin E, protecting retinal lipids and proteins.

4. Vitamin E (natural mixed tocopherols)
   Dose: 100–200 IU/day if supplementing; avoid high doses without advice.
   Function/Mechanism: Lipid-phase antioxidant stabilizes photoreceptor membranes.

5. Zinc (with copper)
   Dose: 25–40 mg/day zinc with 2 mg copper to avoid deficiency.
   Function/Mechanism: Cofactor in retinal enzymes and antioxidant defense; use balanced formulas.

6. Alpha-lipoic acid
   Dose: 300–600 mg/day.
   Function/Mechanism: Redox-active antioxidant improves mitochondrial function; studied in diabetic neuropathy and may support retinal metabolism.

7. Coenzyme Q10 (ubiquinone/ubiquinol)
   Dose: 100–200 mg/day.
   Function/Mechanism: Electron transport cofactor; supports energy production and reduces oxidative stress.

8. Curcumin (with piperine or phytosomal forms)
   Dose: 500–1,000 mg/day (standardized), with absorption enhancer.
   Function/Mechanism: NF-κB–modulating anti-inflammatory actions; may help systemic inflammation that can worsen edema.

9. Resveratrol
   Dose: 100–250 mg/day.
   Function/Mechanism: Antioxidant with vasoprotective effects; supports microvascular health.

10. Bilberry extract (standardized anthocyanins)
    Dose: 80–160 mg standardized extract BID.
    Function/Mechanism: Anthocyanins may enhance night visual function and capillary stability (evidence modest).

---

Regenerative / stem-cell” drugs

Critical safety note: Unregulated “stem cell” eye injections have caused severe, permanent vision loss. The items below are research directions or historical enzymes—not approved cures for VMT. Discuss clinical trials with a qualified retina specialist; avoid commercial clinics promising cures.

1. Next-generation pharmacologic vitreolysis (research)
   Concept: Enzymes or biologics targeting the vitreoretinal interface more selectively than ocriplasmin.
   Mechanism: Break specific adhesion molecules to induce gentle PVD (posterior vitreous detachment).
   Status: Experimental; not standard of care.

2. Hyaluronidase-based vitreolysis (historical/experimental)
   Concept: Modify vitreous viscosity/structure.
   Mechanism: Enzymatic degradation of hyaluronan to reduce gel cohesion.
   Status: Safety/efficacy for VMT unresolved; not recommended clinically.

3. Chondroitinase/dispase (preclinical cautionary enzymes)
   Mechanism: Degrade extracellular matrix components.
   Status: Animal studies raised toxicity concerns; not used clinically for VMT.

4. Mesenchymal stem cell therapies (various routes)
   Mechanism: Theoretical paracrine repair and anti-inflammatory signals.
   Status: Avoid outside regulated trials—serious complications (retinal detachment, inflammation, blindness) reported.

5. iPSC-derived retinal cell replacement (future directions)
   Mechanism: Replace damaged retinal cells in advanced macular disease.
   Status: Aimed at degenerations like AMD, not VMT traction itself; early-stage research.

6. Platelet-derived biologics (e.g., PRP) — not for VMT
   Mechanism: Growth factors for surface healing in other parts of the eye.
   Status: Not indicated for VMT; intravitreal use is not standard and may be risky.

Bottom line: For traction, the proven interventional paths today are ocriplasmin, pneumatic vitreolysis (gas), and vitrectomy. Anything “regenerative” for VMT should be considered experimental only.

---

Surgeries/procedures

1. Pars plana vitrectomy (PPV)
   Procedure: In the operating room, tiny instruments remove the vitreous gel, peel tractional tissue if present, and relieve macular pulling.
   Why it’s done: Definitive way to stop traction, especially with persistent symptoms, macular edema, or macular hole risk.

2. PPV with internal limiting membrane (ILM) peel
   Procedure: After vitrectomy, the surgeon stains and gently peels the ILM (the retina’s innermost layer).
   Why: Reduces tangential forces and lowers the chance of recurrent ERM or traction; often used if an ERM or hole is present.

3. PPV with epiretinal membrane (ERM) peel
   Procedure: Removes the thin scar sheet that can add extra “sideways” pull.
   Why: Improves macular contour and can sharpen vision distorted by ERM plus VMT.

4. Pneumatic vitreolysis (intravitreal gas injection)
   Procedure: In the office or OR, a small gas bubble (e.g., C3F8 or SF6) is injected; you may need specific head positioning to let the bubble lift the vitreous away from the macula.
   Why: Minimally invasive alternative to surgery for select VMTs (especially focal adhesions) and some small macular holes.

5. Combined phaco-vitrectomy (cataract + PPV in one session)
   Procedure: Cataract removal with lens implantation plus vitrectomy during the same operation.
   Why: Efficient if a significant cataract is already present or expected to worsen after vitrectomy.

---

 Prevention tips

You can’t fully “prevent” age-related vitreous changes, but you can protect macular health and catch problems early:

1. Annual (or advised) dilated eye exams after age 50, sooner if symptoms.

2. Prompt OCT if you notice new distortion, blur, floaters, or flashes.

3. Control diabetes, blood pressure, and cholesterol.

4. Don’t smoke (or quit if you do).

5. Wear protective eyewear during risky activities to avoid eye trauma.

6. Follow safe lifting and breathing (avoid forceful Valsalva) when possible.

7. Keep inflammation under control (treat uveitis and systemic inflammatory disease).

8. Review medications with your doctors if swelling occurs.

9. Maintain a retina-friendly diet (leafy greens, colorful produce, fish; see below).

10. Use the Amsler grid weekly to spot changes early.

---

When to see a doctor (red flags)

• Sudden wavy lines or a new central blur (days to weeks).

• New floaters or flashes of light (possible vitreous shift or retinal tear).

• A curtain/shadow in any part of vision (possible retinal detachment—emergency).

• After eye trauma (even if vision seems okay).

• After cataract or other eye surgery if vision changes.

• Diabetics noticing any new distortion or central blur.

• If you have VMT and symptoms are worsening or not improving as expected.

---

What to eat and what to avoid

Things to prioritize

1. Dark leafy greens (spinach, kale) for lutein/zeaxanthin.

2. Oily fish (salmon, sardines, mackerel) 2–3×/week for omega-3s.

3. Colorful fruits/veggies (berries, citrus, bell peppers) for vitamin C and carotenoids.

4. Nuts and seeds (almonds, walnuts, flaxseed) for vitamin E and healthy fats.

5. Legumes and whole grains for steady blood sugar and fiber.

6. Olive oil and other unsaturated fats to reduce inflammation.

7. Eggs (yolks have lutein/zeaxanthin).

8. Hydration (water/unsweetened tea) for general ocular comfort.

9. Spices like turmeric (with pepper) and ginger for anti-inflammatory support.

10. Balanced zinc and copper sources (beans, pumpkin seeds, fortified foods).

Things to limit/avoid

1. Smoking and secondhand smoke.

2. Highly processed foods and trans fats.

3. Excess sugar/high-glycemic snacks (spikes worsen vascular stress).

4. Excess salt (fluid retention can aggravate edema tendencies).

5. Heavy alcohol use (moderate if at all).

6. Overuse of screen brightness/harsh glare without breaks.

7. Energy drinks and stimulants that elevate blood pressure.

8. Crash diets that lead to nutrient deficits.

9. Unverified internet “cures” or unregulated stem cell clinics.

10. Skipping prescribed follow-up visits.

---

Frequently Asked Questions

1. Can VMT go away by itself?
   Yes. A meaningful share of cases spontaneously release within months. Regular OCT checks show whether traction is easing or worsening.

2. How do glasses or cataract surgery affect VMT?
   Glasses improve focus but don’t fix traction. Cataract surgery can change the vitreous dynamics; your surgeon will monitor your macula closely before and after.

3. What is the most reliable way to stop the traction?
   Vitrectomy is the definitive method. Pneumatic vitreolysis helps in select cases. Ocriplasmin may work for some focal adhesions.

4. Will anti-VEGF shots fix the traction?
   No. They treat swelling and leakage from other diseases. They can improve vision if edema is present but don’t reliably release VMT.

5. How does a gas bubble help?
   A correctly placed gas bubble can lift the vitreous off the macula as it rises, especially with proper head positioning. Not all VMTs are suitable.

6. Is vitrectomy safe?
   Modern vitrectomy is highly effective, but risks include infection, bleeding, retinal tear/detachment, cataract progression, and pressure changes. Your surgeon will explain your individual risk.

7. What is an epiretinal membrane (ERM), and why peel it?
   ERM is a thin scar layer on the macula that adds sideways pulling. Peeling it during vitrectomy reduces distortion and improves macular shape.

8. Can exercise or yoga release traction?
   Exercise benefits overall health, but it doesn’t dissolve vitreous adhesions. Avoid forceful Valsalva maneuvers; otherwise, normal activity is generally fine unless your doctor says otherwise.

9. How long is recovery after vitrectomy?
   Many patients notice improvement within weeks; visual recovery can continue for months as the macula re-shapes. If a gas bubble is used, you’ll have positioning guidelines and no air travel until it’s gone.

10. Will I need surgery in both eyes?
    VMT can be unilateral or bilateral. The other eye is monitored; treatment depends on symptoms and OCT findings.

11. Is ocriplasmin a one-time shot?
    Usually one injection is given. Your doctor assesses release and vision over the next few weeks.

12. What if I’m pregnant or planning pregnancy?
    Many drugs/procedures are timing-sensitive in pregnancy. Tell your doctor; plans can often be adjusted to balance safety and vision needs.

13. Can VMT cause permanent damage?
    Persistent traction can lead to macular hole or chronic edema that might reduce best-possible vision. Timely treatment limits this risk.

14. Will supplements cure VMT?
    No. Supplements support overall retinal health but do not release traction. They are add-ons, not cures.

15. How is VMT different from a macular hole?
    VMT is pulling on the macula; a macular hole is a full-thickness gap in the macula’s center. VMT can lead to a hole if traction persists.

 

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: August 30, 2025.